CDKN2A and cancer: Compared with HPV-/p16- cancers, patients with HPV +/p16+ cancers had significant improved OS (HR = 0.30, 95% CI: 0.17–0.51), and patients with HPV+/p16- cancers had no significant improved OS (HR = 0.65, 95% CI: 0.21–2.04) (Figure 2).